Biophysical characterization of the SARS-CoV2 spike protein binding with the ACE2 receptor explains increased COVID-19 pathogenesis
R Chowdhury et al, BIORXIV, April 12, 2020
R Chowdhury et al, BIORXIV, April 12, 2020
Insights on early mutational events in SARS-CoV-2 virus reveal founder effects across geographical regions
C Farkas et al, BIORXIV, April 12, 2020
C Farkas et al, BIORXIV, April 12, 2020
We describe early mutational events across samples from publicly available sequences. Of 30 high quality datasets, 27 datasets (90%) contain at least a single founder mutation and most of the variants are missense (over 63%). Five-point mutations with clonal (founder) effect were found in USA sequencing samples.
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)- A Review
JAM Sanders et al, JAMA, April 13, 2020
JAM Sanders et al, JAMA, April 13, 2020
No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is currently is being tested in ongoing randomized trials.
Who Is Immune to the Coronavirus? About this question, too, decisions with great consequences are being made, as they must be, based on only glimmers of data.
M Lipsitch, NY Times, April 13, 2020
M Lipsitch, NY Times, April 13, 2020
How digital data collection can help track covid-19 cases in real time
E Topol, Washington Post, April 10, 2020
E Topol, Washington Post, April 10, 2020
No other method provides continuous, real-time monitoring of people besides digital technologies. To contemplate reopening our economy without putting public health at unnecessary risk, we need a practical strategy that exploits our digital infrastructure.
No hay comentarios:
Publicar un comentario